Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Energizer Holdings $400 million notes offering
The high-yield notes are due 2033
Strive acquisition of Semler Scientific
We are advising Strive on the acquisition
Oruka Therapeutics $180 million private placement
The PIPE included common stock and pre-funded warrants
British American Tobacco $750 million notes offering
The investment-grade notes are due 2033
Grayscale CoinDesk Crypto 5 ETF approved as first U.S. multi-asset crypto ETF
We advised Grayscale on securing SEC approval for the NYSE Arca listing
Applied Materials $1 billion senior notes offering
The investment-grade notes are due 2031 and 2036
GenFleet Therapeutics HK$1.82 billion IPO
We advised GenFleet on its IPO and HKEX listing
Baldwin Group $1.006 billion credit facilities financing
We advised the borrower on the refinancing and amendment
Oscar Health $410 million convertible senior subordinated notes and capped call transactions
The 2.25% convertible notes are due 2030
Norwegian Cruise Line Holdings comprehensive refinancing transactions
The transactions included new debt, exchangeable debt, registered direct equity offerings and concurrent tender offers